chr9-96235548-G-A
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_000197.2(HSD17B3):c.845C>T(p.Pro282Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000217 in 1,613,920 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. P282P) has been classified as Likely benign.
Frequency
Consequence
NM_000197.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
HSD17B3 | NM_000197.2 | c.845C>T | p.Pro282Leu | missense_variant | 11/11 | ENST00000375263.8 | |
SLC35D2-HSD17B3 | NR_182427.1 | n.3612C>T | non_coding_transcript_exon_variant | 26/26 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
HSD17B3 | ENST00000375263.8 | c.845C>T | p.Pro282Leu | missense_variant | 11/11 | 1 | NM_000197.2 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152246Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000319 AC: 8AN: 250756Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135544
GnomAD4 exome AF: 0.0000192 AC: 28AN: 1461674Hom.: 0 Cov.: 31 AF XY: 0.0000206 AC XY: 15AN XY: 727100
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152246Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74382
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 05, 2016 | The P282L pathogenic variant in the HSD17B3 gene has been reported previously in association with 17-beta hydroxysteroid dehydrogenase 3 deficiency in multiple individuals in the heterozygous state in the presence of a second HSD17B3 variant (Andersson et al., 1996; Boehmer et al., 1999; Phelan et al., 2015). Additionally, functional studies in transfected 239 cells with the P282L variant show that this variant inactivates the enzyme (Andersson et al., 1996). The P282L variant was not observed at any significant frequency in approximately 6500 individuals of European and African American ancestry by the NHLBI Exome Sequencing Project. The P282L variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved in mammals. In silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret P282L as a pathogenic variant. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 22, 2023 | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 282 of the HSD17B3 protein (p.Pro282Leu). This variant is present in population databases (rs144809928, gnomAD 0.03%). This missense change has been observed in individuals with autosomal recessive 17-beta hydroxysteroid dehydrogenase 3 deficiency (PMID: 8550739, 10599740, 25740850). ClinVar contains an entry for this variant (Variation ID: 265484). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on HSD17B3 protein function. Experimental studies have shown that this missense change affects HSD17B3 function (PMID: 8550739). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Testosterone 17-beta-dehydrogenase deficiency Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 26, 2024 | Variant summary: HSD17B3 c.845C>T (p.Pro282Leu) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 250756 control chromosomes. c.845C>T has been reported in the literature in compound heterozygous individuals affected with Testosterone 17-beta-dehydrogenase deficiency (Andersson_1996, Boehmer_1999, Phelan_2015). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity in an in vitro assay (Andersson_1996). The following publications have been ascertained in the context of this evaluation (PMID: 8550739, 10599740, 25740850). ClinVar contains an entry for this variant (Variation ID: 265484). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 30, 2019 | - - |
Pseudohermaphroditism Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital | Feb 01, 2005 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at